Home Medizin Boehringer begrenzt die Selbstbeteiligungskosten für Inhalatoren auf 35 US-Dollar pro Monat

Boehringer begrenzt die Selbstbeteiligungskosten für Inhalatoren auf 35 US-Dollar pro Monat

von NFI Redaktion

(Reuters) – Boehringer Ingelheim announced on Thursday that it will limit out-of-pocket costs for the company’s inhalation products for chronic lung disease and asthma to $35 per month starting on June 1.

The company stated that this new program will drastically reduce costs for patients at the pharmacy counter, including those who are uninsured or underinsured.

The high healthcare costs in the United States have been a cause of great concern for lawmakers and politicians, with reducing these costs being a significant part of President Joe Biden’s reelection campaign in 2024.

„Discussions about prescription drug prices are ongoing, and we have listened. We believe it is important to provide solutions that benefit patients now, while continuing to work with policymakers and other stakeholders on a broader system reform,“ the company said.

Boehringer also announced that it will reduce the list price for some of its inhalation products, without providing further details.

The company has lowered the out-of-pocket costs for its entire range of inhalation products, including Atrovent, Combivent Respimat, and Spiriva HandiHaler, used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), a disease commonly affecting smokers.

COPD, or „smoker’s lung,“ which progressively damages the lungs, affects about 16 million Americans and is the sixth leading cause of death in the country according to the Centers for Disease Control and Prevention.

Last June, the U.S. Food and Drug Administration (FDA) approved the first generic version of Boehringer’s Spiriva HandiHaler from Indian pharmaceutical company Lupin Ltd.

Spiriva, once a top-selling lung medication for controlling COPD symptoms, faces pressure from generic competition in Europe and competing medications such as GSK Plc’s Advair and Roche’s Xolair.

Boehringer was accused in a federal lawsuit in Boston on Wednesday of unlawfully submitting patents to the FDA to delay generic competition and drive up prices for its lung medications Combivent Respimat and Spiriva Respimat.

(Reporting by Pratik Jain in Bengaluru; Editing by Shinjini Ganguli)

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.